Chimerism after Liver Transplantation for Type IV Glycogen Storage Disease and Type 1 Gaucher's Disease

Abstract

Background-Liver transplantation for type IV glycogen storage disease (branching-enzyme deficiency) results in the resorption of extrahepatic deposits of amylopectin, but the mechanism of resorption is not known.

Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance

“…If, as we eventually concluded (5,6,14,35,36), chimerism, differing only in degree in different kinds of organs, is an integral feature of all successful engraftments, any transplantation procedure could result in a gain of metabolic function as suggested for different reasons by Groth et al (69) two decades ago. The chimerism in our long-surviving kidney recipients was only one fifth or less of that in the liver recipients.…”

“…prophecy was fulfilled with the further study of two of these recipients after 22 more mo of follow-up, showing that they had systemic chimeras (5,36).…”

“…13). Even with the limited samples available from these patients, it was evident by this time (Table 3) that the cell migration after clinical (5,36) or experimental liver transplantation (16) was a miniversion of bone marrow transplantation (59) (Fig. 1, right).…”

“…In female patients who had been given organs from male donors, the presence in recipient tissues (or blood) of cells with the Y chromosome was considered unequivocal evidence of systemic chimerism (14,35). Alternatively, probes were used that detected human leukocyte antigen (HLA) alleles of chromosome 6 (5,14,36). For study of either the Y chromosome or chromosome 6, one or the other of two technologies, and usually both, was used (5, 14, 35, HEPATOLO~Y Vol.…”

“…The immunostaining for the HLA markers was with indirect immunofluorescence, an avidin-biotin-complex immunoperoxidase or both methods, by use of monoclonal antibodies to class I and class II antigen phenotypes present in the donor but not the recipient (5,14,36). The tissue sections were blocked with nonimmune serum from the source of the secondary antibody.…”